Orforglipron vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3502970, OWL833
An oral non-peptide GLP-1 receptor agonist. NDA submitted to FDA with Priority Review. Expected approval by mid-2026.
Also: Semaglutide + Cagrilintide
A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Orforglipron | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Orforglipron is a small molecule that activates GLP-1 receptors similarly to peptide GLP-1 agonists. Being a non-peptide allows oral bioavailability without the special formulation needed for oral semaglutide. | Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1. |
| Common Dosing | Limited community data available See research protocols | Limited community data available See research protocols |
| Administration | Oral tablet daily | Subcutaneous injection weekly |
| Typical Duration | Long-term use expected | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ATTAIN-1 Phase 3 results showed significant weight loss. ATTAIN-MAINTAIN showed it helps maintain weight after injectable GLP-1 treatment. NDA submitted late 2025 with National Priority Voucher for expedited review. | Phase 3 REDEFINE 1 trial showed 22.7% weight loss at 68 weeks, significantly outperforming semaglutide alone (15.8%). NDA submitted to FDA in December 2025. If approved, expected to become the leading obesity treatment. |
Frequently Asked Questions: Orforglipron vs CagriSema
What is the difference between Orforglipron and CagriSema?
Orforglipron is a weight loss peptide that an oral non-peptide glp-1 receptor agonist. nda submitted to fda with priority review. expected approval by mid-2026. CagriSema is a weight loss peptide that a combination of semaglutide and cagrilintide (amylin analog). the most effective weight loss drug candidate, showing 22.7% body weight reduction in phase 3 trials - superior to any single-agent glp-1. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Orforglipron or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. Orforglipron is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Orforglipron and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Orforglipron and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Orforglipron and CagriSema is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.